GSK's Tykerb gains FDA approval for use in combo therapy

01/31/2010 | Reuters

The FDA approved the use of GlaxoSmithKline's breast cancer drug Tykerb in combination with Novartis' Femara to treat hormone- and HER2-positive advanced breast cancer in postmenopausal patients under hormonal therapy. A study showed that cancer progression was suppressed for 35 weeks in women using Tykerb and Femara together, compared with 13 weeks for those who received Femara alone.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC